Laboratorio Antidoping FMSI Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2018
NCT03548766
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Laboratorio Antidoping FMSI | Laboratorio Antidoping FMSI, Rome, Italy

Active Ingredients

Drugs in Phase 3 Trials (2)

allogeneic blood cells (1 trial)

autologous blood (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hematologic Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2